Axxam: Rewind fast forwards to series A
Rewind Therapeutics, a Belgium-based developer of treatments for myelin-related diseases, completed a €15.2m ($18.3m) series A round yesterday that was co-led by subsidiaries of pharmaceutical firms Boehringer Ingelheim and Merck Group
Read full article »
AXXAM is a provider of integrated discovery services to pharmaceuticals, crop protection, fragrances and food and beverage sector.
Read more